This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Soler-Soler, J. Articles by Roca-Llop, J. Search for Related Content PubMed PubMed Citation Articles by Soler-Soler, J. Articles by Roca-Llop, J.

Circulation, Vol 59, 876-879, Copyright © 1979 by American Heart Association

ARTICLES

Effect of verapamil in infants with paroxysmal supraventricular tachycardia

J Soler-Soler, J Sagrista-Sauleda, A Cabrera, J Sauleda-Pares, J Iglesias- Berengue, G Permanyer-Miralda and J Roca-Llop

Twenty-nine consecutive spontaneous attacks of paroxysmal supraventricular tachycardia (PSVT) in 14 infants (mean age 4.4 months) were treated with verapamil. No infant had associated heart disease. Verapamil 1-2 mg i.v was administered over 30 seconds. The dosage varied according to the weight of the infant. Within 60 seconds sinus rhythm was obtained in 28 instances (96.5%). No significant complications were observed. The high effectiveness, rapid action and lack of undesirable side effects observed in this series suggest that verapamil is the drug of choice in the treatment of PSVT in infants without underlying heart disease.